The metaphyseal growth plate of long bones is the structural basis for linear growth and is a dynamic, highly differentiated cartilaginous structure. The proliferation, differentiation, hypertrophy and extracellular matrix formation of chondrocytes are the keys to growth plate development and linear growth. Abnormal growth plate development will lead to short stature, and its mechanism is complex. A variety of regulators regulate growth plate development through different mechanisms. In addition to the classic genes SOX9, ACAN, and RUNX2, in recent years, with the development of genetic testing technology, more pathogenic genes have been discovered. The new regulators are involved in a variety of biological processes, including the extracellular skeleton, intracellular signal transduction, ribosome transcriptional processing, protein ubiquitination modification, and epigenetic modification, enriching the gene regulatory network of short stature. This article reviews the roles of some novel regulatory factors in growth plate development.
ZHANG Su-ping, CHEN Hong, CHEN Rui-min.
Novel regulators of growth plate development[J]. Chinese Journal of Child Health Care. 2022, 30(9): 981-984 https://doi.org/10.11852/zgetbjzz2022-0553
中图分类号：
R33
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Samsa WE, Zhou X, Zhou G. Signaling pathways regulating cartilage growth plate formation and activity[J]. Semin Cell Dev Biol, 2017, 62:3-15. [2] Agirdil Y. The growth plate:A physiologic overview[J]. EFORT Open Rev, 2020, 5(8):498-507. [3] Haraguchi R, Kitazawa R, Imai Y, et al. Growth plate-derived hedgehog-signal-responsive cells provide skeletal tissue components in growing bone[J]. Histochem Cell Biol, 2018, 149(4):365-373. [4] Mackie EJ, Tatarczuch L, Mirams M. The skeleton:A multi-functional complex organ:The growth plate chondrocyte and endochondral ossification[J]. J Endocrinol, 2011, 211(2):109-121. [5] Lefebvre V, Dvir-Ginzberg M. SOX9 and the many facets of its regulation in the chondrocyte lineage[J]. Connect Tissue Res, 2017, 58(1):2-14. [6] Komori T. Runx2, an inducer of osteoblast and chondrocyte differentiation[J]. Histochem Cell Biol, 2018, 149(4):313-323. [7] Zollinger AJ, Smith ML. Fibronectin, the extracellular glue[J]. Matrix Biol, 2017, 60-61:27-37. [8] Lee CS, Fu H, Baratang N, et al. Mutations in fibronectin cause a subtype of spondylometaphyseal dysplasia with “Corner Fractures”[J]. Am J Hum Genet, 2017, 101(5):815-823. [9] Cadoff EB, Sheffer R, Wientroub S, et al. Mechanistic insights into the cellular effects of a novel FN1 variant associated with a spondylometaphyseal dysplasia[J]. Clinical Genetics, 2018, 94(5):429-437. [10] Hanley PC, Kanwar HS, Martineau C, et al. Short stature is progressive in patients with heterozygous NPR2 mutations[J]. J Clin Endocrinol Metab, 2020,105(10):3190-3202. [11] Krejci P, Masri B, Fontaine V, et al. Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis[J]. J Cell Sci, 2005, 118(Pt 21):5089-5100. [12] Shuhaibar LC, Robinson JW, Vigone G, et al. Dephosphorylation of the NPR2 guanylyl cyclase contributes to inhibition of bone growth by fibroblast growth factor[J]. Elife, 2017, 6:e31343. [13] Ke X, Liang H, Miao H, et al. Clinical characteristics of short-stature patients with an NPR2 mutation and the therapeutic response to rhGH[J]. J Clin Endocrinol Metab, 2021, 106(2):431-441. [14] Hisado-Oliva A, Ruzafa-Martin A, Sentchordi L, et al. Mutations in C-natriuretic peptide (NPPC):A novel cause of autosomal dominant short stature[J]. Genet Med, 2018, 20(1):91-97. [15] Wendt DJ, Dvorak-Ewell M, Bullens S, et al. Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism[J]. J Pharmacol Exp Ther, 2015, 353(1):132-149. [16] Huckert M, Stoetzel C, Morkmued S, et al. Mutations in the latent TGF-beta binding protein 3 (LTBP3) gene cause brachyolmia with amelogenesis imperfecta[J]. Hum Mol Genet, 2015, 24(11):3038-3049. [17] Stanley S, Balic Z, Hubmacher D. Acromelic dysplasias:how rare musculoskeletal disorders reveal biological functions of extracellular matrix proteins[J]. Ann N Y Acad Sci, 2021, 1490(1):57-76. [18] Dabovic B, Chen Y, Colarossi C, et al. Bone abnormalities in latent TGF-[beta] binding protein (Ltbp)-3-null mice indicate a role for Ltbp-3 in modulating TGF-[beta] bioavailability[J]. J Cell Biol, 2002, 156(2):227-232. [19] McInerney-Leo AM, Le Goff C, Leo PJ, et al. Mutations in LTBP3 cause acromicric dysplasia and geleophysic dysplasia[J]. J Med Genet, 2016, 53(7):457-464. [20] Guo DC, Regalado ES, Pinard A, et al. LTBP3 pathogenic variants predispose individuals to thoracic aortic aneurysms and dissections[J]. Am J Hum Genet, 2018, 102(4):706-712. [21] Trainor PA, Merrill AE. Ribosome biogenesis in skeletal development and the pathogenesis of skeletal disorders[J]. Biochim Biophys Acta, 2014, 1842(6):769-778. [22] Isidor B, Geffroy L, de Courtivron B, et al. A new form of severe spondyloepimetaphyseal dysplasia:clinical and radiological characterization[J]. Am J Med Genet A, 2013, 161A(10):2645-2651. [23] Le Caignec C, Ory B, Lamoureux F, et al. RPL13 variants cause spondyloepimetaphyseal dysplasia with severe short stature[J]. Am J Hum Genet, 2019, 105(5):1040-1047. [24] Costantini A, Alm JJ, Tonelli F, et al. Novel RPL13 variants and variable clinical expressivity in a human ribosomopathy with spondyloepimetaphyseal dysplasia[J]. J Bone Miner Res, 2021, 36(2):283-297. [25] Witting KF, Mulder MPC. Highly specialized ubiquitin-like modifications:Shedding light into the UFM1 enigma[J]. Biomolecules, 2021, 11(2):255. [26] Di Rocco M, Rusmini M, Caroli F, et al. Novel spondyloepimetaphyseal dysplasia due to UFSP2 gene mutation[J]. Clinical Genetics, 2018, 93(3):671-674. [27] Zhang G, Tang S, Wang H, et al. UFSP2-related spondyloepimetaphyseal dysplasia:A confirmatory report[J]. Eur J Med Genet, 2020, 63(11):104021. [28] Rice SJ, Beier F, Young DA, et al. Interplay between genetics and epigenetics in osteoarthritis[J]. Nat Rev Rheumatol, 2020, 16(5):268-281. [29] Widmann M, Niess AM, Munz B. Physical exercise and epigenetic modifications in skeletal muscle[J]. Sports Med, 2019, 49(4):509-523. [30] Ambros V. The functions of animal microRNAs[J]. Nature, 2004, 431(7006):350-355. [31] Grigelioniene G, Suzuki HI, Taylan F, et al. Gain-of-function mutation of microRNA-140 in human skeletal dysplasia[J]. Nat Med, 2019, 25(4):583-590. [32] Papaioannou G, Mirzamohammadi F, Lisse TS, et al. MicroRNA-140 provides robustness to the regulation of hypertrophic chondrocyte differentiation by the PTHrP-HDAC4 pathway[J]. J Bone Miner Res, 2015, 30(6):1044-1052. [33] Qiu Y, Huang S. CTCF-mediated genome organization and leukemogenesis[J]. Leukemia, 2020, 34(9):2295-2304. [34] Xiang JF, Corces VG. Regulation of 3D chromatin organization by CTCF[J]. Curr Opin Genet Dev, 2021, 67:33-40. [35] Nora EP, Caccianini L, Fudenberg G, et al. Molecular basis of CTCF binding polarity in genome folding[J]. Nat Commun, 2020, 11(1):5612. [36] Jia Z, Li J, Ge X, et al. Tandem CTCF sites function as insulators to balance spatial chromatin contacts and topological enhancer-promoter selection[J]. Genome Biol, 2020, 21(1):75. [37] Tai PWL, Wu H, van Wijnen AJ, et al. Genome-wide DNase hypersensitivity, and occupancy of RUNX2 and CTCF reveal a highly dynamic gene regulome during MC3T3 pre-osteoblast differentiation[J]. PLoS One, 2017, 12(11):e0188056. [38] Min H, Kim HP, Shin JO. Depletion of CTCF induces craniofacial malformations in mouse embryos[J]. Am J Transl Res, 2019, 11(9):6102-6109. [39] Chen F, Yuan H, Wu W, et al. Three additional de novo CTCF mutations in Chinese patients help to define an emerging neurodevelopmental disorder[J]. Am J Med Genet C Semin Med Genet, 2019, 181(2):218-225. [40] Li Y, Haarhuis JHI, Sedeno Cacciatore A, et al. The structural basis for cohesin-CTCF-anchored loops[J]. Nature, 2020, 578(7795):472-476.
PDF(535 KB)
